Blackrock Neurotech Stock
| Valuation | $350M1 |
| Valuation Date | Apr 29, 2024 |
| Implied Valuation | n/a |
| Last Price | $0.83 |
| 52-Week High | $0.85 |
| 52-Week Low | $0.55 |
| YTD Return | +0.00% |
| 1-Year Return | -2.35% |
| 3-Year Return | n/a |
| Total Funding | $210M2 |
| Latest Round Amount | $200M3 |
| Latest Round | Primary |
| Funding Rounds | 2 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Blackrock Neurotech
Blackrock Neurotech is a brain-computer interface company that builds implantable devices designed to help people with paralysis and other neurological disorders regain movement, speech and other lost functions. Its core technology is the Utah Array, an implantable microelectrode array that has been used in human brain implants since 2004 and underpins most BCIs tested in people to date. The company makes money by selling implantable electrodes, hardware and software to research institutions and clinical teams worldwide. It is also developing MoveAgain, an implantable BCI system for paralyzed patients that received FDA Breakthrough Device designation in 2021.
Invest in Blackrock Neurotech
Blackrock Neurotech is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Hiive.
Hiive is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
Related Companies
News
Long-term safety and efficacy of intracortical microstimulation in humans
A July 2026 Science publication reported that Blackrock NeuroPort ICMS remained safe and reliably evoked tactile sensations for up to 10 years across five participants and 168 million stimulation puls...
Decade-Long ICMS Safety Study Published in Science
Researchers published the longest human study of intracortical microstimulation safety using Blackrock's NeuroPort system, showing durable tactile sensations across up to 10 years of implant use.
UC Davis brain implant lets ALS patient speak with 99% accuracy and work full time, no researchers needed
A Nature Medicine follow-up study documents an ALS patient using a speech brain-computer interface built on four Blackrock Neurotech microelectrode arrays for over 3,800 hours across nearly two years ...
Meet the Man Making Music With His Brain Implant
A paralyzed research psychologist with six Blackrock Neurotech Utah arrays implanted in a Caltech study is using his neural signals to generate music in real time. His band incorporated the brain-gene...
Cognixion, Blackrock Neurotech partner on brain-computer interface technology
Blackrock Neurotech will distribute Cognixion's noninvasive Axon-R wearable neural interface to research institutions while continuing to focus on implantable BCI technology.
Blackrock Neurotech to Distribute Cognixion's Axon-R Wearable BCI Platform
Blackrock Neurotech agreed to distribute Cognixion's non-invasive Axon-R neural interface to research institutions, pairing surface EEG with implantable BCI data collection.
Cognixion and Blackrock Neurotech Expand Access to Non-Invasive, Multi-Modal BCI Research with Axon-R
Blackrock Neurotech will act as a non-exclusive distributor of Cognixion's Axon-R wearable brain-computer interface and augmented reality platform, offering the research-grade device to institutions t...
Tether Invests $200M in Blackrock Neurotech
Tether invested $200 million in Blackrock Neurotech for a majority stake, valuing the brain-implant company at roughly $350 million to fund commercialization of its BCI technology.
Tether invested $200M in Blackrock Neurotech, accelerating development and commercialization of implantable BCI technology
Stablecoin issuer Tether invested $200 million in Blackrock Neurotech through its venture arm Tether Evo, becoming the company's majority stakeholder. The capital funds commercialization of its implan...
ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System
SOLANA BEACH, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain...
Blackrock Neurotech, ClearPoint Neuro to Address Neurological Disorders With Novel Brain-Computer Interface Surgical Solution
SOLANA BEACH, Calif. and SALT LAKE CITY, July 21, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and de...
Blackrock Neurotech Closes $10M Financing Round To Advance Development Of Its World-Leading Brain-Computer Interface (BCI) Technology
Blackrock Neurotech closed a $10 million financing round led by Christian Angermayer's re.Mind Capital with participation from Peter Thiel, Tim Sievers and Sorenson Impact's University Venture Fund II...